CJC-1295 + Ipamorelin

IPA/CJC Canada

CJC-1295 and Ipamorelin combine two research peptides that interact with the growth hormone axis through different signalling routes. This makes the blend useful for studying complementary pituitary pathways within a single experimental model.

CJC-1295 is a growth hormone-releasing hormone analogue. Researchers examine how it interacts with GHRH receptors to influence growth hormone and downstream IGF-1 signalling.

Ipamorelin takes a different route through the growth hormone secretagogue receptor. Its selective activity has made it an important subject in research involving natural growth-hormone release and endocrine signalling.

Together, the compounds are studied in models involving metabolism, body composition, muscle biology, tissue maintenance, recovery, sleep-related endocrine activity, and healthy aging. However, each component retains its distinct research mechanism.

Researchers may also explore Ipamorelin as a single component or compare the blend with Tesamorelin, another GHRH analogue studied in metabolic and pituitary research.

For researchers seeking CJC-1295 and Ipamorelin in Canada, this blend offers a convenient model for investigating complementary growth-hormone signalling pathways and their downstream metabolic activity.

For laboratory and research purposes only. Not intended for human or veterinary use, diagnosis, treatment, or consumption.